[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,661,173
  • Shares Outstanding, K 98,489
  • Annual Sales, $ 673,000 K
  • Annual Income, $ -575,000 K
  • EBIT $ -561 M
  • EBITDA $ -530 M
  • 60-Month Beta 0.31
  • Price/Sales 4.05
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 102.38% (-10.70%)
  • Historical Volatility 56.73%
  • IV Percentile 87%
  • IV Rank 43.26%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 28) 3.09 (11.42%)
  • Put/Call Vol Ratio 7.19
  • Today's Volume 23,920
  • Volume Avg (30-Day) 5,334
  • Put/Call OI Ratio 2.73
  • Today's Open Interest 77,647
  • Open Int (30-Day) 50,626
  • Expected Range 23.93 to 30.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.27
  • Number of Estimates 7
  • High Estimate $-1.21
  • Low Estimate $-1.34
  • Prior Year $-1.17
  • Growth Rate Est. (year over year) -8.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.00 +0.07%
on 07/23/26
36.57 -26.11%
on 07/07/26
-1.74 (-6.05%)
since 06/23/26
3-Month
21.33 +26.68%
on 06/02/26
36.57 -26.11%
on 07/07/26
+2.74 (+11.29%)
since 04/23/26
52-Week
18.29 +47.73%
on 03/24/26
39.89 -32.26%
on 12/08/25
-0.99 (-3.53%)
since 07/23/25

Most Recent Stories

More News
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report , detailing the company's work on behalf of patients and families living...

RARE : 27.02 (-2.26%)
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1050 (-0.57%)
LEGN : 23.53 (unch)
RARE : 27.02 (-2.26%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 27.02 (-2.26%)
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

NEW YORK , June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ:...

RARE : 27.02 (-2.26%)
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 27.02 (-2.26%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 27.02 (-2.26%)
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 27.02 (-2.26%)
Ultragenyx: Q1 Earnings Snapshot

Ultragenyx: Q1 Earnings Snapshot

RARE : 27.02 (-2.26%)
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760...

RARE : 27.02 (-2.26%)
Ultragenyx's Conference Call Tomorrow: Still Waiting for Gene Therapy to Pay Rent

Barchart Research What to Expect from RARE Earnings RARE Generated May 4, 2026 Current Price $24.81 EPS Estimate $$-1.55 Consensus Rating Strong Buy Average Move 5.39% Ultragenyx's Conference Call Tomorrow:...

RARE : 27.02 (-2.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 28.76
2nd Resistance Point 28.41
1st Resistance Point 27.71
Last Price 27.02
1st Support Level 26.66
2nd Support Level 26.31
3rd Support Level 25.61

See More

52-Week High 39.89
Fibonacci 61.8% 31.64
Fibonacci 50% 29.09
Last Price 27.02
Fibonacci 38.2% 26.54
52-Week Low 18.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.